APS

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024

"Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."

Key Points: 
  • "Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."
  • To arrange a meeting with management, please contact your Biotech Showcase representative or Lytham Partners at [email protected] .
  • The ceremony will feature healthcare companies within the Nasdaq Biotechnology Index, highlighting them as companies pioneering the future.
  • The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

Ceva Extends its Connect IP Portfolio with Wi-Fi 7 Platform for High-End Consumer and Industrial IoT

Retrieved on: 
Wednesday, January 3, 2024

ROCKVILLE, Md., Jan. 3, 2024 /PRNewswire/ -- Ceva, Inc. (NASDAQ: Ceva), the leading licensor of silicon and software IP that enables Smart Edge devices to connect, sense and infer data more reliably and efficiently, today announced the general release of its next generation RivieraWaves Wi-Fi 7 IP platform, further expanding its widely-licensed portfolio of connectivity IP, targeting high-end consumer and industrial applications including gateways, TVs, set-top-boxes, streaming media devices, AR/VR headsets, personal computing and smartphones. The RivieraWaves Wi-Fi 7 IP leverages all the latest advanced features of the IEEE 802.11be standard to deliver a premium high performance, cost- and power-optimized Wi-Fi solution for integration into the next wave of Wi-Fi Access Point (AP) and Station (STA) products.

Key Points: 
  • Expanding on this leadership position, Ceva's RivieraWaves Wi-Fi 7 IP provides a unique, comprehensive 802.11be MAC and PHY solution for integration into the next generation of Wi-Fi SoC products.
  • Our RivieraWaves Wi-Fi 7 IP platform incorporates all the features of this latest-generation, wireless standard, dramatically simplifying development and time-to-market for companies looking to add Wi-Fi 7 connectivity to their products."
  • Flexible RF interface enables integration with radio circuitry from multiple Ceva partners or licensee's own radio technology.
  • The RivieraWaves Wi-Fi 7 IP platform is available now for Access Point applications, with an optimized Station implementation arriving later this year.

Wi-Fi NOW Awards Akoustis and HPE Aruba Networking for Best Enterprise Wi-Fi Solution

Retrieved on: 
Wednesday, December 20, 2023

Charlotte, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that the Company, along with HPE Aruba Networking, has been awarded the 8th Annual Wi-Fi NOW Awards Gala for the Best Enterprise Wi-Fi Solution.

Key Points: 
  • Charlotte, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that the Company, along with HPE Aruba Networking, has been awarded the 8th Annual Wi-Fi NOW Awards Gala for the Best Enterprise Wi-Fi Solution.
  • HPE Aruba Networking has created Wi-Fi access points (APs) with patented ultra tri-band (UTB), the only solution in the Wi-Fi industry that makes use of all 5 and 6 GHz bands allocated by the FCC for Wi-Fi with no performance degradation on any combination of channels.
  • This solution is an innovative collaboration, combining HPE Aruba Networking’s advanced switch filter architecture and Akoustis’ XBAW® high-performance filter technology, currently being utilized in HPE Aruba Networking 650 Series and 630 Series Wi-Fi 6E APs.
  • The Company continues to secure new design wins in its target markets including Wi-Fi, 5G Infrastructure, and Automotive, many of which are slated to ramp into production in the coming months.

General Atomics Scientist Honored for Career Achievements in Fusion Energy

Retrieved on: 
Tuesday, December 19, 2023

San Diego, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fusion Power Associates (FPA) has awarded one of its 2023 Distinguished Career Awards to General Atomics (GA) fusion scientist Dr. Tony Taylor for his contributions in advancing international fusion energy research.

Key Points: 
  • San Diego, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fusion Power Associates (FPA) has awarded one of its 2023 Distinguished Career Awards to General Atomics (GA) fusion scientist Dr. Tony Taylor for his contributions in advancing international fusion energy research.
  • The FPA Distinguished Career Awards are given annually to individuals who have made distinguished, lifelong career contributions to fusion development.
  • He came to the company in the early 1980s as a senior scientist on the Doublet III program, attracted by the innovation and strong team culture in fusion.
  • Over his more than 40 years in fusion energy research, he served as GA’s Director of Experimental Science, Deputy Director and later Director of DIII-D, and Vice President of Magnetic Fusion Energy.

Nexcella Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Retrieved on: 
Monday, December 18, 2023

LOS ANGELES, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined the Nexcella Scientific Advisory Board.  Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.

Key Points: 
  • Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.
  • I believe recent developments in the CAR-T field allow for novel approaches to treat autoimmune diseases,” said Dr. Radic.
  • “I am excited about joining the Nexcella scientific advisory board and continuing to contribute to expanding treatment options to patients with debilitating autoimmune diseases.”
    "It is a pleasure to welcome Dr. Radic as a member of our Scientific Advisory Board.
  • Prior to joining UTHSC in 2000, Dr. Radic was an Associate Professor in the Department of Microbiology at Drexel University.

Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Retrieved on: 
Monday, December 18, 2023

LOS ANGELES, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”), announced that effective today, Marko Radic PhD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.  Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.

Key Points: 
  • Dr. Radic brings decades of experience in autoimmune cell therapy, and thought leadership to Nexcella.
  • I believe recent developments in the CAR-T field allow for novel approaches to treat autoimmune diseases,” said Dr. Radic.
  • “I am excited about joining the Nexcella scientific advisory board and continuing to contribute to expanding treatment options to patients with debilitating autoimmune diseases.”
    "It is a pleasure to welcome Dr. Radic as a member of our Scientific Advisory Board.
  • Prior to joining UTHSC in 2000, Dr. Radic was an Associate Professor in the Department of Microbiology at Drexel University.

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Retrieved on: 
Thursday, November 30, 2023

SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer.

Key Points: 
  • SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the appointment of Fletcher Payne to Chief Business Officer, in addition to his role as Senior Vice President, Chief Financial Officer.
  • During his career, he has executed a wide array of business transactions totaling more than $3.7 billion, with healthcare focus in clinical testing, oncology, neurological, and orphan diseases indications.
  • “Fletcher’s financial and business oversight has proven to be instrumental as we continue to evolve our business and operations strategies,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.
  • “He brings the strategic leadership necessary at a time of significant opportunity for Aptose.”

Veea to Become Publicly Traded Company via proposed Business Combination with Plum Acquisition Corp. I

Retrieved on: 
Tuesday, November 28, 2023

NEW YORK, NY and SAN FRANCISCO, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Veea Inc. (“Veea” or the “Company”), a digital transformation company, and Plum Acquisition Corp.

Key Points: 
  • NEW YORK, NY and SAN FRANCISCO, CA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Veea Inc. (“Veea” or the “Company”), a digital transformation company, and Plum Acquisition Corp.
  • I (“Plum”, and together, the “Parties”) (Nasdaq: PLMI), a Cayman Islands exempted company formed as a special purpose acquisition company by Ursula Burns, Kanishka Roy and Mike Dinsdale, today announced their entry into a definitive business combination agreement (the “Business Combination Agreement”) related to a proposed merger (such merger and related transactions, including the issuance by Plum of securities in connection therewith, collectively, the “Business Combination”) expected to result in Veea becoming a publicly traded company (referred to herein as the “Combined Company” ) whose business, after the closing (the “Closing”), assuming the occurrence thereof, will be the continued business of Veea.
  • Proceeds from the proposed Business Combination and financing transactions are expected to support the Combined Company in its business plans, including Veea’s mission of positioning itself as a leader of Digital Inclusion across the globe.
  • The proposed Business Combination has, prior to the execution of the Business Combination Agreement, been approved by the boards of directors of each of Veea and Plum.

Medigus: Charging Robotics to Receive Funding from the Israel Innovation Authority for Piloting its Wireless Charging Solution for Automated Parking System

Retrieved on: 
Wednesday, November 22, 2023

Tel Aviv, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) --  Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that Charging Robotics Ltd., an innovator in wireless charging solutions and a subsidiary of Fuel Doctor Holdings, Inc., (“FDOC”) a Delaware corporation listed on the OTC Market (66.84% owned by Medigus), received approval for funding from the Israeli Innovation Authority for a pilot project that includes installing and demonstrating its solution for wireless charging of electric vehicles (EVs) in automated parking systems. The system will be installed and tested in an automated parking system that was installed by Parkomot and meets a growing need for charging EVs in automated parking systems, where drivers aren’t able to connect a charging plug to the EV socket. The total approved budget for this project is approximately NIS 1.2 million ($445,000), of which the Israel Innovation Authority will finance 50%.

Key Points: 
  • The system will be installed and tested in an automated parking system that was installed by Parkomot and meets a growing need for charging EVs in automated parking systems, where drivers aren’t able to connect a charging plug to the EV socket.
  • The total approved budget for this project is approximately NIS 1.2 million ($445,000), of which the Israel Innovation Authority will finance 50%.
  • The approval for the funding, provided by the Israel Innovation Authority, was received after a rigorous due diligence process regarding the technology, the market, the competitive landscape and Charging Robotics’ team.
  • The Israel Innovation Authority provides support for Israeli companies with cutting edge technologies which answer needs in large markets.

Charging Robotics to Receive Funding from the Israel Innovation Authority for Piloting its Wireless Charging Solution for Automated Parking System

Retrieved on: 
Wednesday, November 22, 2023

Tel Aviv, Israel, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Fuel Doctor Inc. (OTC: FDOC), a Delaware corporation, announced today that its wholly owned subsidiary, Charging Robotics Ltd., an innovator in wireless charging solutions, received approval for funding from the Israel Innovation Authority for a pilot project that includes installing and demonstrating its solution for wireless charging of electric vehicles (EVs) in automated parking systems. The system will be installed and tested in an automated parking system that was installed by Parkomot and comes to answer a growing need for charging EVs in automated parking systems, where drivers aren’t able to connect a charging plug to the EV socket.

Key Points: 
  • The system will be installed and tested in an automated parking system that was installed by Parkomot and comes to answer a growing need for charging EVs in automated parking systems, where drivers aren’t able to connect a charging plug to the EV socket.
  • The approval for the funding, provided by the Israel Innovation Authority, was received after a rigorous due diligence process regarding the technology, the market, the competitive landscape and the company team.
  • The Israel Innovation Authority provides support for Israeli companies with cutting edge technologies which answer needs in large markets.
  • "We are honored and thankful to receive this support from The Israel Innovation Authority.